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Background: Translational arrest is a classical 
cellular response to hypoxia whose underlying 
mechanisms are unknown.  
Results: Inhibitory phosphorylation of 
eukaryotic elongation factor 2 by acute hypoxia 
depends on oxygen-sensitive prolyl 
hydroxylases (PHDs). 
Conclusion: Elongation phase of protein 
synthesis is regulated by PHDs. 
Significance: This work unravels a novel 
cellular process controlled by PHDs, potential 
pharmacological targets in several human 
diseases. 
 
SUMMARY 
Early adaptive responses to hypoxia are 
essential for cell survival, but their nature 
and underlying mechanisms are poorly 
known. We have studied the post-
transcriptional changes in mammalian cells’ 
proteome elicited by acute hypoxia and 
found that phosphorylation of eukaryotic 
elongation factor 2 (eEF2), a ribosomal 
translocase whose phosphorylation inhibits 
protein synthesis, is under precise and 
reversible control of O2 tension. Upon 
exposure to hypoxia, phosphorylation of 
eEF2 at Thr56 occurs rapidly (< 15 min) and 
results in modest translational arrest, a 
fundamental homeostatic response to 
hypoxia that spares ATP and thus facilitates 
cell survival. Acute inhibitory eEF2 
phosphorylation occurs without ATP 
depletion or AMP kinase activation. 
Furthermore, eEF2 phosphorylation is 
mimicked by prolyl hydroxylases (PHDs) 
inhibition with dimethyloxalylglycine 
(DMOG) or by selective PHD2 siRNA-
silencing, but is independent of hypoxia 
inducible factor α  stabilization. Moreover, 
over-expression of PHD2 blocks hypoxic 
accumulation of phosphorylated eEF2. 
Therefore, our findings suggest that eEF2 
phosphorylation status, and as a 
consequence translational rate, is controlled 
by PHD2 activity. They unravel a novel 
pathway for cell adaptation to hypoxia that 
could have pathophysiologic relevance in 
tissue ischemia and cancer. 
Cell adaptation to reduced oxygen 
availability to maintain ATP levels is a major 
physiologic challenge since O2 deprivation, 
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even transient, can produce irreversible 
damage. Cellular responses to hypoxia 
comprise transcriptional and non-transcriptional 
mechanisms whose nature is as yet only 
partially known (1-3). Transcriptional 
adaptation to low O2 tension mainly depends on 
hypoxia inducible transcription factors (HIFs), 
master regulators of a broad cohort of genes 
whose expression decreases the cellular O2 
demand and increases O2 supply (3). Cellular 
levels of HIFα are inversely correlated with the 
activity of prolyl hydroxylases (PHDs), O2-
sensing and Fe2+-dependent enzymes that 
hydroxylate specific proline residues in HIFα 
using O2 as co-substrate, thus allowing HIFα 
ubiquitination and proteasomal degradation 
(4,5). 
In contrast with the relatively well-
characterized PHD-HIF pathway, the 
transcription-independent hypoxic adaptive 
mechanisms are poorly known. Nevertheless, 
they are essential for cell survival during the 
first minutes of hypoxia, before functional 
expression of the O2-regulated genes can take 
place (2,6). Global inhibition of protein 
synthesis (“translational arrest”) has been 
classically recognized as a fundamental 
adaptation to hypoxia, since mRNA translation 
is an energy-costly process that consumes up to 
70% of the ATP synthesized by the cells. 
Hence, any small adjustment on translation rate 
can spare sufficient ATP as to immediately 
attend functions critical for cell survival (7-10). 
Several kinases regulated during cell energy 
starvation, in particular the mammalian target 
of Rapamycin (mTOR), the endoplasmic 
reticulum kinase (PERK), and AMP-activated 
protein kinase (AMPK), have been suggested to 
contribute to HIF-independent inhibition of 
protein translation under low O2 conditions 
(7,9,11-13). These phosphorylation/ 
dephosphorylation cascades regulate protein 
synthesis by precisely modulating the activity 
of ribosomal initiation and elongation factors 
(eEF) (10,14). In this regard, elongation factor 
2 (eEF2), a translocase necessary for the 
movement of the mRNA along the ribosome, is 
particularly important as, in conjunction with 
aminoacylation, it uses most of the ATP 
required for protein synthesis (15). eEF2 is 
inhibited by phosphorylation at Thr56 by eEF2 
kinase (eEF2K), (16,17), which in turn is 
activated by AMPK (18). 
Using a proteomic approach designed to 
detect early adaptive changes during short (5-30 
min) exposure to hypoxia, we have identified 
several proteins acutely regulated by O2 
availability. Among these proteins eEF2 was 
also modulated by DMOG, an inhibitor of the 
O2 sensing PHDs. Herein, we describe that 
eEF2 activity is rapidly and reversibly regulated 
by O2 tension in a PHD2-dependent manner. 
This phenomenon is unrelated with HIF 
stabilization and it occurs prior to AMPK 
activation. These observations, that unveil 
unexpected actions of the O2-sensing PHD2, 
could have profound implications for the 
pathophysiology and pharmacology of cell 
adaptation to hypoxia.  
 
EXPERIMENTAL PROCEDURES 
Cell culture and hypoxic treatments–PC12, 
Mlp9, HeLa, and HuH7 cells were cultured in 
DMEM (Bio-Whittaker) supplemented with 
10% FBS (Gibco), 100 U/mL penicillin, 100 
U/mL streptomycin and 2 mM L-glutamine 
(Bio-Whittaker). Cardiac ventricular myocytes 
were prepared from 1- to 3-day-old animals and 
cultured as described by (19). Hepatocytes were 
isolated from male Wistar rats by collagenase 
(Invitrogen) perfusion as described previously 
(44). U2OS Tet-ON and U2OS Tet-ON/pUHD-
Flag-PHD2 cells were cultured in DMEM 
supplemented with 10% tetracycline-free FBS 
(Clontech/Takara), 100 U/mL penicillin, 100 
U/mL streptomycin, and 5 µg/mL Blasticidine 
S (Invitrogen). 200 µg/mL Hygromycin-B 
(Roche) was used in U2OS Flag-PHD2 
cultures. Cells were maintained under water-
saturated atmosphere of 5% CO2-95% air. 
DMOG (Biomol International L.P.) was used at 
a final concentration of 1 mM, NaF (SIGMA) 
was used at 25 mM, and AICAR (SIGMA) at 1 
mM. Okadaic acid (Calbiochem), Sanguinarine 
(SIGMA) were used at the concentrations 
specified. 
Hypoxic conditions (1% O2, 94% N2, and 
5% CO2) were achieved in a humidified 
variable aerobic workstation (Invivo2 300; 
Ruskin). In all experiments, cells were plated at 
30%–50% confluence to prevent the 
development of anaerobic conditions at 1% O2. 
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Before experimentation, media were pre-
equilibrated overnight to the experimental 
oxygen level. 
Protein Analysis–Sample preparation, 
labeling and analysis by 2D-DIGE. Sup100 
protein extracts from PC12 cells were prepared 
and labeled as described (20). 150 µg of labeled 
protein, containing three equal amount extracts 
(Normoxic, Hypoxic or DMOG treated, and the 
internal standard) were used for 2D-DIGE. 
Electrophoretic conditions, quantitative analysis 
of differences, and preparative gels were 
performed as described (20). Four biological 
replicates were used in all the experiments. 
eEF2 purification from rat liver. Rat liver 
were homogenized and eEF2 purified as 
described by (21) using an ÄKTA purifier (GE 
Healthcare). 
Western blot, protein synthesis 
measurements, and MALDI-MS/MS analysis 
are described in the Supplemental methods 
accompanying this paper. 
RNA interference–Transfections of 
siRNAs were carried out using Lipofectamine 
2000 (Invitrogen) at a final concentration of 20 
nM. Previously validated sequences of siRNAs 
were used (22,23). However the efficacy of the 
transfection in each experiment was ascertained 
by immunoblotting and/or RT-qPCR. Non-
published siRNAs and oligonucleotides 
sequences can be found in Supplemental 
methods. 
ATP Measurements–ATP levels in cell 
extracts were determined by ATP 
bioluminescence assay kit CLS II (Roche 
Applied Science) using GLOMAXTM 96 
microplate luminometer equipped with an auto-
injection device (Promega). 
Statistics–Data are presented as mean ± 
S.E.M. and were analyzed with one-way 
analysis of variance followed by Tukey’s test. p 
< 0.05 was considered statistically significant. 
 
RESULTS 
Acute O2-Dependent Modulation of Cell 
Proteome–We performed proteomic (2D-
DIGE) analyses of soluble subcellular fractions 
(S100) (20) obtained from homogenates of 
PC12 cells exposed to normoxia (21% O2) or 
hypoxia (1% O2) for 15 to 30 min. A 2D map of 
the S100 fraction is shown in Fig. 1a with spots 
whose relative amounts increased (red), 
decreased (green), or were unchanged (yellow) 
in hypoxia. Among the 2598 spots detected, 24 
were identified in all the experimental 
replicates and changed their relative amount in 
hypoxia versus normoxia (> 1.5-fold and p < 
0.05. See Supplemental Table I). In 2D gels, 
eEF2 appeared in a strip of spots that could 
correspond to additive modifications of the 
protein (Fig. 1A, white rectangle), hence we 
extended our analysis to additional neighboring 
spots. These modifications are probably due to 
different diphthamide content in eEF2. Among 
the 7 spots studied (Fig. 1B, top), 5 were 
identified as eEF2 by MALDI-MS(/MS) 
(asterisks), and all were recognized by an anti-
eEF2 antibody (Fig. 1B, middle). Accordingly, 
eEF2 purified from rat liver and separated in a 
2D electrophoresis showed a similar 
distribution (Fig. 1B, bottom). These results 
revealed that eEF2 is modified by short 
exposure to hypoxia, thus suggesting that it 
could be a mediator of the early adaptive 
mechanisms triggered by low O2 tension. 
It is known that eEF2 activity is inhibited 
by phosphorylation at Thr56 through a specific 
eEF2 kinase (16,17). Therefore, we tested in 
several cell types whether the changes in eEF2 
observed in the 2D-DIGE analyses correlated 
with modifications in eEF2 Thr56 
phosphorylation status using specific P-Thr56 
antibodies. Hypoxia (1% O2) produced a 
marked increase in eEF2 phosphorylation that 
was detectable 15 min after exposure of cells to 
low O2 tension. Total amount of eEF2 was 
unchanged by exposure to hypoxia (Fig. 1C-E; 
SFig. 1A, B). 
Inhibitory eEF2 Phosphorylation in Acute 
Hypoxia Occurs Before ATP Depletion and 
AMPK Activation–As mentioned before, 
several kinases modulated by energy starvation 
are also regulated during sustained hypoxic 
conditions (7,9,12,13,18). AMPK, activated by 
phosphorylation at Thr172 by liver kinase B1 
(LKB1) when the AMP/ATP ratio increases 
(24-27), can activate eEF2K through 
phosphorylation at Ser398 (18) and thus induce 
inhibitory Thr56 phosphorylation of eEF2 
(16,17). We postulated that the fast, O2-
dependent modulation of eEF2 reported here 
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should occur prior to, and independently of, 
AMPK activation. 
As expected, exposure of hepatocytes to 
1% O2 revealed a clear increase in eEF2-Thr56 
phosphorylation detectable as soon as 5 min 
after O2 deprivation, without any increase in the 
levels of active AMPK (phosphorylated at 
Thr172). In contrast, cells treated with 5-
aminoimidazole-4-carboxiamide riboside 
(AICAR), an AMPK activator used as a control 
(28), showed strong activation of AMPK (Fig. 
2A). Short-lasting exposure to hypoxia also 
resulted in an increase of eEF2-P-Thr56 and 
decrease of AMPK-P-Thr172 levels in other cell 
types analyzed (Fig. 2B). Interestingly, the 
amount of active AMPK during hypoxic 
exposures lasting up to 4 h remained even 
lower than the value in normoxia (Fig. 2A, B). 
In fair agreement with these data, cellular ATP 
concentration did not change (or even 
increased) after 15 or 60 min in hypoxia (1% 
O2) (Fig. 2C). The activity of eEF2K is 
inhibited by phosphorylation at Ser366, a process 
regulated by p90RSK/p70S6 kinases (18). Short 
hypoxia did not produce any changes in the 
cellular levels of eEF2K-P-Ser366 (Figure 1C). 
Hypoxia treatment did not alter the total levels 
of eEF2, eEF2K, or AMPK (Fig. 1C, 2B). 
Hypoxia and Prolyl Hydroxylase 2 
Inhibition Increase eEF2 Phosphorylation in a 
HIF-Independent Manner–To test whether 
some of the identified proteins modified by 
hypoxia could be under the control of the O2 
sensing PHDs, cells were exposed to 
dimethyloxalylglycine (DMOG), a competitive 
inhibitor of 2-oxoglutarate-dependent 
dioxygenases, including PHDs (4,29). Control 
(untreated) and 15 min DMOG-treated cells 
were processed by 2D-DIGE and a 
representative gel of the S100 fraction is shown 
in Fig. 3A, with proteins whose relative 
amounts increased (green), decreased (red), or 
were unchanged (yellow) after DMOG 
treatment. Only spot 1, identified by mass 
fingerprinting analysis as eEF2, changed both 
in hypoxia (see Fig. 1A) and after DMOG 
treatment (Fig. 3A). As hypoxia, DMOG 
treatment also elicited in several cell types a 
similar P-Thr56 eEF2 accumulation although 
with a slower time course (Fig. 3B-D; SFig. 
1B). DMOG-triggered accumulation of either 
HIF-1α or HIF-2α, used as controls (Fig. 3C, 
D), was also delayed compared to hypoxia, thus 
possibly reflecting DMOG cellular uptake and 
metabolization to the active N-oxalylglycine 
inhibitor. 
As transformed cell lines normally show 
some resistance to hypoxic translational arrest 
(30), we estimated if the increase in 
phosphorylation of eEF2 by short hypoxia or 
DMOG induced a concomitant decrease in 
protein translation in primary cultured 
hepatocytes (Fig. 3E). As expected, hypoxic 
and DMOG treatments resulted in a significant 
decrease in protein synthesis rate as determined 
by 35S-met incorporation assay (Fig. 3F). 
Hypoxia and DMOG rapidly inhibit PHDs, 
therefore the involvement of these enzymes in 
modulation of protein synthesis was studied 
using cells incubated with siRNA specific to 
each PHD (22). We observed a selective 
increase of eEF2-P-Thr56 after PHD2 silencing, 
and no effect after inhibition of either PHD1 or 
PHD3 (Fig. 4A). The effectiveness of the 
siRNA treatment on PHDs mRNA was 
confirmed by qRT-PCR (Supplemental Table 
II). PHD2 silencing was also demonstrated by 
selective stabilization of HIF-1α (Fig. 4A). 
PHD down-regulation studied in several cell 
types always correlated with 
hyperphosphorylation of eEF2 at Thr56 (SFig. 
2A). 
To further prove the direct involvement of 
PHD2 in the regulation of eEF2 by acute 
hypoxia we have used a cell line (U2OS) where 
PHD2 expression is conditionally induced by 
doxycycline (Norma Masson and Peter 
Ratcliffe, unpublished material).  
Overexpression of PHD2 is known to inhibit 
stabilization of HIF-1 and 2α in hypoxia 
(23,31), hence we tested whether PHD2 
overexpression also prevents eEF2 
phosphorylation by acute hypoxia. After 4 h in 
doxycycline, expression of PHD2 was observed 
in U2OS cells (Fig. 4B) and was correlated 
with a clear decrease in the amount of eEF2 
phosphorylated after 30 min of hypoxic 
treatment (Fig. 4B; see quantification in Fig. 
4C, p = 0.024). As a control, we tested that 
HIF-1α stabilization by hypoxia was also 
partially prevented by PHD2 expression (Fig. 
4B; see  quantification in   Fig. 4C, p = 0.044). 
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Because inhibition of PHD2 by hypoxia, 
DMOG, or siRNA leads to HIF-α 
accumulation, we investigated whether HIF 
might regulate eEF2 phosphorylation at Thr56. 
Although expression of either HIF-1α or HIF-
2α in hypoxia was clearly abolished using 
specific siRNAs, eEF2 phosphorylation was 
unaltered (Fig. 4D, upper panel). Hypoxia-
dependent eEF2 phosphorylation was observed 
even though HIF-1α and HIF-2α were 
simultaneously silenced to prevent possible 
compensatory effects of any of the isoforms 
(Fig. 4D, bottom panel). The dispensability of 
HIFα for the hypoxic/DMOG-induced eEF2 
phosphorylation was further confirmed by 
using a genetically modified embryonic stem 
cell line lacking HIF-1α (32), (SFig. 2B). 
eEF2 phosphorylation by hypoxia is 
reversible and strongly controlled by 
phosphatases activity–Accumulation of 
phosphorylated eEF2 under hypoxia was 
rapidly (< 15 min) reversed upon 
reoxygenation, independently of the duration of 
the hypoxic treatment (Fig. 5A), thus 
supporting the notion that O2-dependent eEF2 
phosphorylation is indeed a tightly regulated 
process. Furthermore, inhibition of Ser/Thr 
phosphatases with sodium fluoride (NaF) 
produced a marked increase in the amount of 
eEF2-P-Thr56, which was not further modified 
by subsequent exposure to hypoxia. In contrast, 
phosphorylation of eEF2K at Ser366, used as 
control for phosphatase activity, was 
unchanged. Hence, eEF2-P-Thr56 appears to be 
highly susceptible to the action of phosphatases 
(Fig. 5B). To identify the phosphatase acting on 
eEF2 we have used inhibitors more specific 
than NaF. It has been described that eEF2 can 
be dephosphorylated by PP2A and PP2C 
(33,34). Hence, we tested specific inhibitors for 
each phosphatase and analyzed where they 
reproduce the fast changes in the level of 
phosphorylation of eEF2 observed under 
hypoxia. Short okadaic acid treatment (a PP2A 
inhibitor) produced a strong accumulation of 
eEF2 (Figure 5C, left panel), but sanguinarine 
(a PP2C inhibitor) did not affect the 
phosphorylation status of eEF2 (Figure 5C, 
right panel). These results suggest that PP2A 
control the phosphorylation status of eEF2 
under normoxia. 
 
DISCUSSION 
In this report we describe selective post-
transcriptional adaptive changes in mammalian 
cells’ proteome elicited by acute hypoxia. This 
study focuses on eEF2, a translocase necessary 
for protein synthesis, although we have 
identified two other proteins (arginyl 
aminopeptidase and protease inhibitor 
Serpinb6) also altered by lowering O2 tension 
(See Supplemental Table I). We show that 
hypoxic inhibitory eEF2 phosphorylation is 
independent of AMPK activity and is mimicked 
by DMOG treatment, thus suggesting the 
notion that eEF2 activity and protein synthesis 
are modulated by PHDs. 
Translational arrest is a classically studied 
cellular response to anoxia or long-term 
hypoxia (for a review see 14). It has also been 
reported that short (2 h) exposure to moderate 
hypoxia (0.2-2% O2) can lead to a modest but 
reproducible decrease in translation efficiency 
(35), an effect that is better observed with 
longer (> 24 h) treatments (12,13,36,37). We 
show here that acute (5-15 min) hypoxia (1% 
O2) or DMOG treatment leads to changes on 
eEF2 migration pattern as a consequence of 
increased protein phosphorylation at Thr56. It is 
well established that phosphorylation of eEF2 
at Thr56 decreases the rate of protein elongation 
(17,38), a mechanism that can contribute to 
mRNA translation inhibition by hypoxia and 
DMOG observed in primary cultured 
cardiomyocytes (Fig. 3F). Similar results have 
been reported using tumor/immortalized cell 
lines (12,13) but longer periods, more severe 
hypoxia, or even concomitant serum 
withdrawal were required to observe a decrease 
in protein synthesis in these cellular models that 
are normally resistant to mRNA translation 
inhibition by hypoxia (30). 
The activation of the AMPK/eEF2K/eEF2 
pathway to arrest protein translation under 
long-term hypoxia or ischemia has been 
elegantly demonstrated in previous reports 
(12,13). However, the inhibition of eEF2 
activity observed under acute hypoxia 
described here is independent of this pathway. 
Indeed, we have shown that short-term hypoxia 
even decreases AMPK activity in all cells 
tested (Fig. 2A, B). In agreement with this data, 
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cellular ATP levels were preserved or increased 
upon acute exposure to acute hypoxia (Fig. 2C) 
(see also 13,39). The existence of 
complementary PHD2- and AMPK-dependent 
eEF2 modulator pathways set in motion 
depending on O2 availability is advantageous 
because it offers a broader adaptive repertoire 
to ensure ATP homeostasis. 
As DMOG inhibits a broad family (> 50 
members) of 2-oxoglutarate-dependent 
dioxygenases (4,29), we performed siRNA 
analyses to identify the PHDs involved in eEF2 
regulation. We have found that selective 
inhibition of PHD2 in several cell lines leads to 
a sustained eEF2 phosphorylation at Thr56, thus 
confirming that protein synthesis is modulated 
by the activity of the O2 sensor PHD2 (Fig. 4A 
and SFig. 2B). To achieve a strong silencing of 
PHD2, cells were treated with siRNAs for 72 h, 
inducing several HIF-regulated pathways that 
could, indirectly, lead to phosphorylation of 
eEF2. However, over-expression of PHD2 for 4 
h produces a strong inhibition of the hypoxia 
dependent phosphorylation of eEF2 (Fig. 4B, 
C), an effect that has been also shown for 
hypoxia-induced HIF stabilization (23,31). 
Altogether, these data suggest a control of 
PHD2 over the elongation phase of protein 
translation. PHD2-dependent regulation of 
translation is independent of HIF-α activity and 
takes place few minutes after PHDs inhibition 
(Fig. 4C and SFig. 2B). Sequence analyses 
reveal the presence in eEF2 of three motifs 
consisting of a proline preceded by two 
neighboring leucines (LXLXP), resembling the 
hydroxylation consensus motifs (LXXLAP) 
existing in the O2-dependent degradation 
domain (ODDD) of HIF-α (4,5). However, 
additional work will be required to determine if 
PHD2 regulates eEF2 by direct hydroxylation 
of these residues or, alternatively, modulates 
the activity of other proteins, including eEF2K 
or any subunit of the cellular phosphatases. 
O2 influx to tissues can be a fluctuating 
condition (40), thus the mechanisms regulating 
hypoxic responses must be reversible and easily 
adjustable to oxygen availability. Interestingly, 
phosphorylation of eEF2 is tightly regulated by 
the activity of specific kinases and 
phosphatases (33,34,36). We show here that 
phosphorylation of eEF2 at Thr56 by hypoxia is 
quickly reversed upon returning to normoxia 
(Fig. 5A). Short exposure (10 min) of cells to a 
Ser/Thr phosphatase inhibitor lead to marked 
accumulation of phosphorylated eEF2, 
indicating a high basal activity of phosphatases 
acting on eEF2 (Fig. 5B). Our pharmacological 
studies revealed that acute inhibition of PP2A 
activity leads to a similar accumulation of 
phosphorylated eEF2 (Fig. 5C), suggesting a 
role of this protein in the regulation of protein 
synthesis by acute hypoxia. The tightly 
regulation and the fast reversibility of eEF2 
phosphorylation/dephosphorylation status make 
this protein an ideal candidate to control protein 
synthesis rate in response to variable conditions 
of tissue O2 availability. 
In conclusion, we propose a novel 
mechanism that helps explain acute translation 
arrest in hypoxia, which is AMPK- and HIF-
independent, and relies on PHD2-mediated 
regulation of eEF2 activity (see scheme in Fig. 
6). However, complete understanding of the 
mechanism whereby PHD2 regulates eEF2 
phosphorylation must await further 
investigation. Besides its obvious interest in the 
biology of hypoxia and hypoxia/reperfusion, 
the PHD2-eEF2 pathway could open new 
perspectives relevant for the pharmacology of 
tissue ischemia and cancer. 
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FOOTNOTES 
 
1The abbreviations used are: DMOG, dimethyloxalylglycine; PHDs, prolyl hydroxylases; HIFs, 
hypoxia inducible transcription factors; mTOR, mammalian target of Rapamycin; PERK, 
endoplasmic reticulum kinase; LKB1, liver kinase B1; AMPK, AMP-activated protein kinase; eEF, 
eukaryotic elongation factors; eEF2K, eEF2 kinase; AICAR, 5-aminoimidazole-4-carboxiamide 
riboside; NaF, sodium fluoride 
 
FIGURE LEGENDS 
 
FIGURE 1. Acute inhibitory eEF2 phosphorylation (Thr56) is induced by hypoxia. A. 
Representative 2D gel. Extracts from normoxic (21% O2, green) or hypoxic (1% O2, 15 min; red) 
PC12 cells migrated in the same gel. Numbered spots correspond to the spots listed in Supplemental 
Table I. The internal standard extract is not shown in the image. B. Same spots as those included 
inside the white rectangle in “a” labeled with CyDyes from a different 2D-gel (top). Five spots 
(asterisks) were identified as eEF2 by peptide mass fingerprinting analysis. Western blot of the 
marked spots using an anti-eEF2 antibody (α-eEF2, center). eEF2 purified from rat liver, separated 
by 2D electrophoresis and detected by Sypro staining (bottom). C. Phosphorylation of eEF2 (Thr56) 
in HuH7 subjected to normoxia (N) or hypoxia (H: 1% O2) for 15 to 240 min. Levels of eEF2K, 
eEF2k-Ser366, ß-actin, HIF-1α, and 2α were analyzed in the same cell extracts. D. Quantification of 
eEF2-P-Thr56 levels in (C) (r.u.: relative units). E. Hepatocytes subjected to normoxia (N) or 
hypoxia (H: 1% O2) for 15 min. Two independent experiments are shown. Total levels of eEF2 and 
ß-actin were analyzed by Western blot. 
 
FIGURE 2. Inhibitory eEF2 phosphorylation in acute hypoxia is independent of AMPK activity. A. 
Phosphorylation of eEF2 (Thr56) and AMPK (Thr172) analyzed by Western blot in hepatocytes 
subjected to hypoxia (H) for 5-240 min or treated with the AMPK activator AICAR for 240 min as 
a control. B. Phosphorylation of eEF2 (Thr56) and AMPK (Thr172) analyzed by Western blot in 
PC12 (left panels) or HuH7 (right panels) cells exposed to normoxia (N) or hypoxia (H) for 5 or 15 
min. Total AMPK, eEF2K, and ß-actin were used as loading controls. C. ATP levels in HeLa (left 
bars) and HuH7 (right bars) cell lysates exposed to normoxia (N) or hypoxia (H) for 15 or 60 min. 
Dashed lines represent normoxic levels; (n = 5; *p < 0.05). 
 
FIGURE 3. Acute inhibitory eEF2 phosphorylation (Thr56) induced by DMOG treatment. A. 
Representative 2D gel showing protein extracts from control (red) or DMOG-treated (green) cells. 
The encircled spot was differentially expressed after DMOG treatment and is similar to spot 1 in 
Fig. 1A. The rectangle represents the same area of the gel shown in Fig. 1A.  B. A 2D gel region 
showing spots modified by hypoxia (upper panel) and DMOG (bottom panel). C. Phosphorylation 
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of eEF2 (Thr56) in HuH7 subjected to normoxia (N) or DMOG (1 mM) for 15 to 240 min. Levels of 
eEF2K, eEF2K-Ser366, ß-actin, HIF-1α, and 2α were analyzed in the same cell extracts. D. 
Quantification of eEF2-P-Thr56 levels in (C) (r.u.: relative units). E. Hepatocytes subjected to 
normoxia (N) or DMOG (1 mM) for 15 min. Two independent experiments are shown. Total levels 
of eEF2 and ß-actin were analyzed by Western blot. F. Protein synthesis (35S-Met incorporation) in 
cardiomyocytes exposed to normoxia (N), DMOG, or hypoxia (H) for 4 hours. Data are represented 
relative to N; (n = 5; *p < 0.05). 
 
FIGURE 4. Hypoxic eEF2 phosphorylation is regulated by PHD2 in a HIF independent manner. A. 
Phosphorylation of eEF2 (Thr56) and levels of HIF-1α examined by Western blot 48 h after siRNA 
transfection. HeLa cells were transfected with either PHD siRNAs or with a non-silencing scramble 
siRNA (Control). Control cells were independently subjected to hypoxia (H) for 15 min. In all the 
experiments, sample loading was normalized with total eEF2 and ß-actin. B. Hypoxic eEF2 
phosphorylation at Thr56 is prevented by acute PHD2 overexpression. Phosphorylation of eEF2 in 
control or PHD2-expressing U2OS cells (Flag-PHD2). Cells were treated with doxycycline (Dox) 
for 4 h when indicated (+) and subjected to normoxia (N) or hypoxia (H, 1% O2) for 30 min. Levels 
of HIF-1α and Flag-PHD2 were analyzed in the same cell extracts. Total levels of eEF2 and ß-actin 
were also analyzed by Western blot. C. Quantification of the fold change produced in the levels of 
eEF2-P-Thr56 (black bars) and HIF-1α (gray bars) by 30 min of hypoxia in the absence (–) or the 
presence (+) of Dox in FLAG-PHD2 cell cultures (*, p < 0.05, n = 3). D. Hypoxic eEF2 
phosphorylation at Thr56 is independent of HIF-α activity. HeLa cells were transfected with a 
scrambled siRNA (Control), siHIF-1α, siHIF-2α (upper panels), or both (bottom panels) for 24 hr, 
and exposed to hypoxia (H) for 0, 15, or 240 min. Levels of eEF2-P-Thr56, eEF2, HIF-1α, HIF-2α, 
and ß-act were analyzed by Western blot. 
 
FIGURE 5. Phosphorylation of eEF2 at Thr56 is dynamic. A. Levels of eEF2 phosphorylation 
(Thr56) in HuH7 cells subjected to hypoxia (H) for 15 (upper panel) or 60 (lower panel) min and 
recovery after returning to normoxia for 15-240 min (Reox). B. Phosphorylation of eEF2 (Thr56) 
and eEF2K (Ser366) in HeLa cells treated with the Thr/Ser phosphatase inhibitor NaF (25 mM) for 
10 min. Cells were also exposed to normoxia (N) or hypoxia (H) for 15 min. Total level of eEF2K, 
eEF2, and ß-actin were also analyzed by Western blot. C. Phosphorylation of eEF2 at Thr56 is 
enhanced by short okadaic acid treatment (OA, 250 nM; left panel) and not affected by treatment 
with sanguinarine (SA, 0.5-2.5 µM, right panel). NaF (25 mM) treatment was performed as a 
control. 
 
FIGURE 6. Schematic representation of the eEF2 cycle in the ribosome (blue drawing). In 
normoxia (left), eEF2K/Protein Phosphatase (PP) balance is displaced to the unphosphorylated form 
of eEF2 (green balls) in a PHD2 dependent process. Acute hypoxia (center) inhibits PHD2 activity 
and leads to increased eEF2 phosphorylation (red balls), which slows down the eEF2 cycle. In 
sustained hypoxia or anoxic/ischemic conditions (right), AMPK is activated, which leads to 
stimulatory eEF2K phosphorylation (Ser399), eEF2 phosphorylation, and strong inhibition of 
elongation rate. 
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Supplemental data  
Supplemental methods 
Western blotting. Cells were homogenized in Laemmli sample buffer. Protein concentrations were 
determined by the RC-DC method (Biorad). Lysates (25-50 μg) were resolved on 8% SDS-
polyacrylamide gel electrophoresis followed by transfer to Protein Blotting polyvinylidene difluoride 
membranes (GE Healthcare). Membranes were probed with the different antibodies (see below) and 
developed with ECL plus Western blotting detection system (GE Healthcare). Antibodies and dilutions 
used are: eEF2, Phospho-eEF2 (Thr56), eEF2K, and Phospho-eEF2K (Ser366) (1:1,000; Cell Signaling); 
AMPK (1/500; Upstate) and AMPK-P-Thr172 (1/1,000; Cell Signaling); HIF-1α (1:500; Cayman) (1); 
HIF-2α (1:1,000; Abcam); and β-actin (1:5,000; Abcam).  
Quantification of protein synthesis. Cardiomyocytes were exposed to normoxia, hypoxia (1%) or 
DMOG (1 mM) for 4 h in serum-free medium. Cells were exposed to Met-free DMEM media 
supplemented with 0.68 mCi/ml 35S-Met and incubated for additional 15 min under the same conditions. 
Then, the cells were washed in cold PBS and lysed in RIPA buffer containing complete protease inhibitor 
cocktel (SIGMA). Proteins were precipitated using TCA. 35S-Met incorporation was measured using a 
Malisa Star Liquid Scintillation Counter. The amount of radioactivity incorporated was normalized to the 
protein content of each sample. 
Mass spectrometry analysis. MALDI Peptide mass fingerprint and LIFT TOF/TOF spectra were 
measured on a 4800 plus MALDI TOF/TOF Analyzer (Applied Biosystems). Mass measurements were 
performed in positive ion reflector mode using 140 ns delayed extraction and a nitrogen laser (337 nm). 
The laser repetition rate was 50 Hz and the ion acceleration voltage was 25 kV. Mass measurements were 
performed automatically through fuzzy logic based software to accumulate 100 single laser shot spectra 
or manually to accumulate 200 single laser shot spectra. Each spectrum was internally calibrated with the 
mass signals of three trypsin autolysis ions: [VATVSLPR+H]+ (m/z = 842.510), [LSSPATLNSR]+ (m/z 
= 1045.564) and [LGEHNIDVLEGNEQFINAAK+H]+ (m/z = 2211.105) to reach a typical mass 
measurement accuracy of ± 20 ppm. Known trypsin and keratin mass signals, as well as potential sodium 
adducts (+21.982 Da) or signals arising from methionine oxidation (+15.995 Da) were removed from the 
peak list. The measured tryptic peptide masses exported from the Applied Biosystems 4000 Series 
Explorer Software v3.5.3 were transferred through Global Proteome Server workstation (v3.0 Applied-
Biosystems) as inputs to search the NCBInr database (2008. 06. 28; 6655203 sequences; 2281585098 
residues) using Mascot Software (v1.9, Matrix Science). Search default parameters were as follow: 
cystein complete carbamidomethylation, methionine partial oxidation, 100 ppm maximal peptide 
tolerance, and 1 maximal protease missed cleavage. Database search was restricted to mammal 
sequences. The acceptance criteria was a Mascot score bigger that 71. This score indicates a p < 0.05. 
MS/MS analysis was performed by default with the three ions with the highest abundance in the digested 
sample. The mass tolerance for fragment ions was 0.2 Da and the cut-off score value for accepting 
individual MS/MS spectra was a total ion score above 30 in combination with a confidence index above 
98.6 %. MS/MS data from LIFT TOF/TOF spectra were combined with MS peptide mass fingerprint data 
for database searching using Global Proteome Server workstation. The acceptance criteria was the Mascot 
p < 0.05 threshold (Mascot score above 76). All the MALDI-MS spectra obtained are shown in the 
supporting information. Analysis was performed at SCAI facilities of “Universidad de Cordoba” (Spanish 
proteomic network, “Proteored”). 
siRNA and oligonucleotide sequences. 
Rat siRNAs: 
siRNA control: 5’-CCCUACAUCCCGAUCGAUGdTdT-3’ 
siRNA PHD1: 5’- UCAGAACUGGGAUGUUAAGdTdT-3’ 
siRNA PHD2: 5’- GGUGAGCGGAGGUAUUCUUdTdT-3’ 
siRNA PHD3: 5’- GCAGGAAUCCACAUGAAGUdTdT-3’ 
Oligonucleotides used in qRT-PCR 
PHD1 
Human, Mouse, and Rat PHD1 (hPHD1.2; 65bp)  
 Forward: 5’-TGACCGGTTGCTCATTTTCTG-3’ 
 Reverse: 5’-TGGCATAGGCTGGCTTCAC-3’ 
PHD2 
Human, Mouse, and Rat PHD2 (mPHD2; 68 bp) 
 Forward: 5’-AGCTGGTCAGCCAGAAGAGT-3’ 
 Reverse: 5’-GCCCTCGATCCAGGTGATCT-3’ 
PHD3 
Human PHD3 (hPHD3.2; 70 bp) 
 Forward: 5’-GGCTGGGCAAATACTACGTCAA-3’ 
 Reverse: 5’-CCTGTTCCATTTCCCGGATAG-3’ 
Mouse and Rat PHD3 (mPHD3; 66 bp) 
 Forward: 5’-CAGACCGCAGGAATCCACAT-3’ 
 Reverse: 5’-CATCGAAGTACCAGACAGTCATAGC-3’ 
HOUSE-KEEPING 
Human 36B4 (Rplp02h; 69 bp) 
 Forward: 5’-CAGATTGGCTACCCAACTGTT-3’ 
 Reverse: 5’-GGCCAGGACTCGTTTGTACC-3’ 
Mouse and Rat 36B4 (Arbp01m; 50 bp)  
 Forward: 5’-TCCAGGCTTTGGGCATCA-3’ 
 Reverse: 5’-CTTTATCAGCTGCACATCACTCAGA-3’ 
 
Supplemental figures: 
SFig. 1. A. Cardiomyocytes (left), PC12 (middle), and Mlp29 (right) cell lines were subjected to hypoxia 
(H: 1% O2) for 0-240 min, and phosphorylation at Thr56 of eEF2 was examined. The levels of HIF-1α 
were analyzed in the cardiomyocytes extracts. B. Phosphorylation of eEF2 (Thr56) in HeLa cells subjected 
to normoxia (N), hypoxia (H: 1% O2) or DMOG (1 mM) for 0-240 min. Levels of HIF-1α and 2α were 
analyzed in the same cell extracts. Total level of eEF2 and ß-actin were also analyzed by Western blot. 
 
SFig. 2. A, left. Phosphorylation of eEF2 (Thr56) and levels of HIF-1α examined by Western blot 48 h 
after siRNA transfection. HuH7 cells were transfected with either PHD siRNAs or with a non-silencing 
scramble siRNA (Control). Control cells were independently subjected to hypoxia (H) for 15 min. In all 
the experiments, sample loading was normalized with total eEF2 and ß-actin. A, right. PC12 cells were 
transfected with siRNAs targeting the three PHDs, or with two different non-silencing control siRNAs 
(Control 1 and 2). Control cells were independently subjected to hypoxia (H) for 15 min. The eEF2 
phosphorylation at Thr56 and total levels of eEF2 were examined by Western blot 24 h after transfection. 
B. Wild-type (HIF-1α+/+: left) or HIF-1α deficient (HIF-1α–/–: right) mouse ES cells were exposed to 
DMOG (1 mM) or hypoxia (Hyp: 1% O2) for 0 to 240 min. Levels of eEF2-P-Thr56, eEF2, HIF-1α, and 
ß-act were examined by Western blot. 
 
 
Supplemental Table I: 
Spots modified by hypoxia and DMOG treatments. 
       
     15 min Hypoxia 30 min Hypoxia 15 min DMOG   
ID1 Protein accession 
Number 
Protein Name (Gen name) p value Fold 
change2 
p value Fold 
change2 
p value Fold 
change2 
M.S.3 
1 NP_058941 Eukaryotic translation elongation factor 2 (eEF2) 0.01400 1.51 0.03950 1.62 0.0129 1.66 312 
2    0.03860 1.76 0.01050 2.03 n.s.c.4 n.s.c.   
3    0.01842 1.51 0.00312 1.75 n.s.c. n.s.c.   
4    0.00710 1.56 0.00043 1.79 n.s.c. n.s.c.   
5    0.02961 1.61 0.00410 2.16 n.s.c. n.s.c.   
6    0.01241 1.72 0.00422 1.96 n.s.c. n.s.c.   
7    0.03458 1.65 0.01777 1.80 n.s.c. n.s.c.   
8    0.00168 1.61 0.02707 2.30 n.s.c. n.s.c.   
9    0.02834 1.52 0.00244 1.75 n.s.c. n.s.c.   
10    0.02483 1.56 0.01844 1.62 n.s.c. n.s.c.   
11       0.00470 1.52 0.00379 1.51 n.s.c. n.s.c.   
12    0.00415 1.55 0.02765 1.54 n.s.c. n.s.c.   
13 NP_112359 Arginyl aminopeptidase (Rnpep) 0.01183 1.70 0.00819 1.74 n.s.c. n.s.c. 513 
14    0.00750 -1.61 0.00265 -1.71 n.s.c. n.s.c.   
15    0.01729 1.52 0.01383 1.51 n.s.c. n.s.c.   
16    0.00634 1.84 0.00111 2.44 n.s.c. n.s.c.   
17    0.00940 1.64 0.00987 1.75 n.s.c. n.s.c.   
18    0.00806 -1.52 0.00747 -1.55 n.s.c. n.s.c.   
19 NP_954516 
Serine peptidase inhibitor; 
clade B; member 6a 
(Serpinb6a) 
0.00074 1.58 0.00019 1.59 n.s.c. n.s.c. 197 
20    0.00011 1.51 0.01903 1.73 n.s.c. n.s.c.   
21 NP_001014139 
Ubiquitin-like domain 
containing CTD phosphatase 1 
(Ublcp1) 
0.00149 1.61 0.00057 1.68 n.s.c. n.s.c. 68 
22    0.01073 1.58 0.00008 1.86 n.s.c. n.s.c.   
23    0.00401 -1.52 0.00516 -1.59 n.s.c. n.s.c.   
24    0.01140 -2.96 0.02500 -3.01 n.s.c. n.s.c.   
1. ID numbers correspond to spots encircled in Fig. 1; 2. Positive values applies to spots with increased levels in hypoxia or DMOG, negative ones 
to relative amounts increased in Normoxia; 3. M.S.: Mascot Score; 4.  n.s.c.: No significant change. 
 
Arginyl aminopeptidase removes arginine and/or lysine residues from the amino terminal end of proteins (2) and is 
required for neuropeptides maturation, including enkephalin, a well-known vasodilator of cerebral arteries (3, 4). This 
enzyme seems to be implicated in inflammatory responses and tumor progression (5). The protease inhibitor Serpinb6 
has also been related with inflammation and protection against cerebral ischemia (6). Nonetheless, whether Serpinb6 
and arginyl aminopeptidase play any relevant role in O2 homeostasis is a question not addressed in the current study and 
left for future experimental work. 
  
Supplemental Table II. Efficiency of siRNA treatments.
SIMA 100
PHD1 (siPHDs) 38.85
PHD2 (siPHDs) 30.17
PHD3 (siPHDs) 33.77
SIMA 100
HIF1 (siHIFs) 4.18
EPAS (siHIFs) 4.14
PHD1 (siPHD1) 36.78
PHD1 (siPHDs) 22.98
PHD2 (siPHD2) 24.38
PHD2 (siPHDs) 32.06
PHD3 (siPHD3) 13.87
PHD3 (siPHDs) 29.26
HeLa silencing of HIF/PHDs                                                                                                                                
PC12 silencing of PHDs with siPHD1+2+3                                                                                                                                
Supplemental references: 
 
1. Ginouves A, Ilc K, Macias N, Pouyssegur J, Berra E (2008) PHDs 
overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells 
from necrosis. Proc Natl Acad Sci U S A 105:4745-4750. 
2. Foulon T, Cadel S, Cohen P (1999) Aminopeptidase B (EC 3.4.11.6). Int J 
Biochem Cell Biol 31:747-750. 
3. Balogh A, et al. (1998) Aminopeptidase B: a processing enzyme secreted and 
associated with the plasma membrane of rat pheochromocytoma (PC12) cells. J 
Cell Sci 111:161-169. 
4. Benyo Z, Wahl M (1996) Opiate receptor-mediated mechanisms in the 
regulation of cerebral blood flow. Cerebrovasc Brain Metab Rev 8:326-357. 
5. Piesse C, et al. (2002) Human aminopeptidase B (rnpep) on chromosome 
1q32.2: complementary DNA, genomic structure and expression. Gene 292:129-
140. 
6. Nakaya N, Nishibori M, Wang Z, Sakiyama J, Saeki K (1998) The expression 
and localization of serine proteinase inhibitor PI-6 mRNA in developmental and 
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